| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/04/2007 | CN1990037A Thymosin alpha1 active fragment and polyethylene glycol derivative thereof |
| 07/04/2007 | CN1989963A Pharmaceutical compositions |
| 07/04/2007 | CN1324215C Emergency door opening system |
| 07/04/2007 | CN1324132C Snake venom thrombin-like enzyme and its encoding gene and application |
| 07/04/2007 | CN1324045C Protein separated from jellyfish and possessing antioxygenation activity and its application |
| 07/04/2007 | CN1324018C Oligopeptides and compositions containing them as cathepsin S inhibitors |
| 07/04/2007 | CN1324008C Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2007 | CN1323722C Positional isomers of PEG IFN alpha 2a |
| 07/04/2007 | CN1323717C Buccal tablet of recombined human interferon alpha 1 b and its preparation |
| 07/04/2007 | CN1323716C Use of SAPR-1 for the treatment and/or prevention of scleroderma |
| 07/04/2007 | CN1323715C Use of C-ski gene and its polypeptide in preparing medicine for improving tissue repairing and reducing scar formation |
| 07/04/2007 | CN1323714C PEGlyated Chinese trichosannthes root protein medicine and its preparation |
| 07/04/2007 | CN1323713C Novel usage of soluble P-lectin and anthrax lethal toxin |
| 07/04/2007 | CN1323658C Novel dry powder inhalation system for transpulmonary administration |
| 07/03/2007 | US7238799 Mustang, a gene and nuclear protein |
| 07/03/2007 | US7238796 Oncogenic protein for use in diagnosis, prevention and treatment of cell proliferative disorders of nervous ystem |
| 07/03/2007 | US7238790 PRO1313 polypeptides |
| 07/03/2007 | US7238787 PRO polypeptides; monoclonal/humanized antibodies; fusion proteins |
| 07/03/2007 | US7238783 Used for creening for potential therapeutic compounds that inhibit the integrin-binding or -interacting activities of recombinant collagen-like proteins |
| 07/03/2007 | US7238779 Comprises acyl CoA:cholesterol acyltransferase polypeptide for use in treatment and prevention of gall stones; enzyme inhibitors |
| 07/03/2007 | US7238778 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| 07/03/2007 | US7238776 TNF binding proteins |
| 07/03/2007 | US7238775 Receptor(SSTR4)-selective somatostatin analogs |
| 07/03/2007 | US7238774 Statine derivatives for the treatment of Alzheimer's disease III |
| 07/03/2007 | US7238685 E.g., substituted 2,3,5,10b-tetraaza-benzo[e]azulen-6-yl)-acetic acids, 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl)-(4,6-dimethoxy-pyrimidin-2-yloxy)-acetic acids and 2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-ylmethyl}-benzoates; treating vasoconstriction, proliferation and inflammation |
| 07/03/2007 | US7238675 consisting of a substantially uncharged antisense oligomer with ratio of uncharged linkages to charged linkages in the oligomer is at least 4:1, preferably at least 5:1, and more preferably at least 8:1 |
| 07/03/2007 | US7238674 In situ injection; transduction; sustained release |
| 07/03/2007 | US7238671 coadministration with and at least one therapeutic agent selected from the group consisting of an antidiabetic agent, an anti-obesity agent, a anti-hypertensive agent, an anti-atherosclerotic agent and a lipid-lowering agent |
| 07/03/2007 | US7238670 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 07/03/2007 | US7238669 Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
| 07/03/2007 | US7238668 Exposing the lymphocytes to a peptide that binds to alpha 4 beta 1, consisting of three to twelve contiguous amino acid residues of the CS-1 region of fibronectin; suppression of the immune response |
| 07/03/2007 | US7238667 Albumin fusion proteins |
| 07/03/2007 | US7238666 Method of inhibiting fibrosis with a somatostatin agonist |
| 07/03/2007 | US7238665 Mimetic peptide conjugated to therapeutic liposome for use as a drug delivery tool in treatment of cell proliferative disorders; tissue engineering |
| 07/03/2007 | US7238663 Comprising a GLP-1 compound and an acylated basal insulin or a pI shifted basal insulin; can be used to treat diseases such as non-insulin dependent diabetes mellitus and insulin dependent diabetes mellitus, hyperglycemia, obesity |
| 07/03/2007 | US7238662 Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof |
| 07/03/2007 | US7238661 Oral lactoferrin in the treatment of respiratory disorders |
| 07/03/2007 | US7238659 Local, regionally-restricted delivery to an axon in situ of an ubiquitin-proteasome system inhibitor, optionally in conjunction with a microtubule stabilizing reagent, and detection the resultant reduction in axon trauma or axotomyn |
| 07/03/2007 | US7238658 Treating agonist disorders including obesity, and hyperglycemic, whole body growth, immunological, kidney, neurological and neuromuscular disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern |
| 07/03/2007 | US7238657 Cartilage/Bone inducing materials for preparation |
| 07/03/2007 | US7238656 Protective factors against inflammation, burns and noxious stimuli |
| 07/03/2007 | US7238529 Methods and compositions for treating ocular disorders |
| 07/03/2007 | US7238528 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 07/03/2007 | US7238510 Glycoprotein synthesis |
| 07/03/2007 | US7238506 Electron transport proteins |
| 07/03/2007 | US7238499 Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids |
| 07/03/2007 | US7238489 Identification of sortase gene |
| 07/03/2007 | US7238488 Therapeutic and diagnostic applications of perlecan domain I splice variants |
| 07/03/2007 | US7238478 Compositions and methods for protein isolation |
| 07/03/2007 | US7238475 Transgenic animal comprising apolipoprotein A-IV (APOAV) for diagnosing, evaluating and treating lipid-related, diabetic, cardiovascular and coronary diseases; insulin resistance; reduced triglycerides |
| 07/03/2007 | US7238368 Releasable linkage and compositions containing same |
| 07/03/2007 | US7238360 Getting the same result as gene therapy, without the introduction of exogenous DNA, by binding T cell with immunomodulator biotin, then contacting with avidin or streptavidin; apoptosis induction or resistance |
| 07/03/2007 | US7238359 A Proline-proline-glutamic acid family antigenic protein shows a strong B-cell immune response |
| 07/03/2007 | US7238358 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 07/03/2007 | US7238357 Methods for treating ulcers and gastroesophageal reflux disease |
| 07/03/2007 | US7238356 Core-glycosylated HCV envelope proteins |
| 07/03/2007 | US7238354 Method of treating atopic dermatitis using antibody against human interleukin-5 receptor alpha chain |
| 07/03/2007 | US7238352 Methods and compositions for modulating tumor growth |
| 07/03/2007 | US7238350 Phytase polypeptides |
| 07/03/2007 | US7238346 An Ad5 left terminus, a promoter, a Factor VIII cDNA wherein the B- domain has been deleted; and an Ad5 right terminus. |
| 07/03/2007 | US7238344 Interferon-β variants and conjugates |
| 07/03/2007 | CA2367131C Methods for fine powder formation |
| 07/03/2007 | CA2361987C Goodpasture antigen binding protein |
| 07/03/2007 | CA2333465C Growth differentiation factor promoter and uses therefor |
| 07/03/2007 | CA2319096C Method for treating acute intermittent porphyria (aip) and other porphyric diseases |
| 07/03/2007 | CA2295199C Method for treating vascular proliferative diseases with p27 and fusions thereof |
| 07/03/2007 | CA2277429C A lactoferrin tablet |
| 07/03/2007 | CA2256413C Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| 07/03/2007 | CA2243302C Anti-human vegf receptor f1t-1 monoclonal antibody |
| 07/03/2007 | CA2216611C Utrophin gene promoter |
| 07/03/2007 | CA2174122C Therapeutic delivery compositions and methods of use thereof |
| 07/03/2007 | CA2158869C Recombinant virus, process for preparing the same and use thereof in gene therapy |
| 07/03/2007 | CA2092567C Nt-4 neurotrophic factor |
| 06/28/2007 | WO2007073186A2 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
| 06/28/2007 | WO2007073147A1 Apoptosis-inducing protein complexes and therapeutic use thereof |
| 06/28/2007 | WO2007073127A1 Anticancer agent comprising a peptide |
| 06/28/2007 | WO2007072997A1 Metastin derivatives and use thereof |
| 06/28/2007 | WO2007072980A1 Novel application of apelin |
| 06/28/2007 | WO2007072977A1 Pharmaceutical composition for allergic disease |
| 06/28/2007 | WO2007072845A1 Therapeutic agent or therapeutic method for ischemic stroke |
| 06/28/2007 | WO2007072186A2 Use of alpha-msh for treatment of fibroproliferative disorders |
| 06/28/2007 | WO2007072037A1 Cyclic antimicrobial peptides |
| 06/28/2007 | WO2007072011A1 Interleukin- 9 like receptor protein |
| 06/28/2007 | WO2007071992A1 Casein-like secreted protein |
| 06/28/2007 | WO2007071874A2 Novel compounds which interact with pea-15 |
| 06/28/2007 | WO2007071789A1 Means and methods for mediating protein interference |
| 06/28/2007 | WO2007071449A1 Soluble gp130 molecule variants useful as a medicament |
| 06/28/2007 | WO2007071448A2 Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
| 06/28/2007 | WO2007071395A1 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| 06/28/2007 | WO2007071390A1 Method for treating malignant melanoma |
| 06/28/2007 | WO2007071068A1 Process for the production of preformed conjugates of albumin and a therapeutic agent |
| 06/28/2007 | WO2007071053A1 Markers for memory t cells and uses thereof |
| 06/28/2007 | WO2007071045A1 Catecholamine regulated protein |
| 06/28/2007 | WO2007070983A1 Transdermal delivery of pharmaceutical agents |
| 06/28/2007 | WO2007070899A2 Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms |
| 06/28/2007 | WO2007053952B1 Platelet factor-4 (pf-4) analogs and their use |
| 06/28/2007 | WO2007051975A3 Compositions comprising igbpma and uses thereof |
| 06/28/2007 | WO2007051431A3 Stable formulations containing enhancing proportions of gamma- and alpha-interferons |
| 06/28/2007 | WO2007049977A3 Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases. |
| 06/28/2007 | WO2007047919A3 Treatment of restenosis and stenosis with dasatinib |